NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has been added to the Russell Microcap Index, effective at the market open on June 29, as part of the 2026 Russell indexes reconstitution. The addition means the company's stock will be included in the widely followed index, which is used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
The semi-annual reconstitution of the Russell US Indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000 Index automatically includes stocks in the large-cap Russell 1000 Index or small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes. The Russell Microcap Index consists of the smallest 1,000 securities in the Russell 2000 Index, plus the next 1,000 smallest eligible securities by market cap.
Being added to the Russell Microcap Index is a significant milestone for NeuroOne, as it can lead to increased visibility and potential investment from index funds that track the index. According to data as of June 2025, about $12.2 trillion in assets are benchmarked against the Russell US indexes, according to FTSE Russell, the global index provider that manages the indexes.
NeuroOne is a medical technology company focused on improving surgical care for patients with neurological disorders. The company markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions.
The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. NeuroOne's inclusion in the Russell Microcap Index may attract more attention from investors and analysts, potentially supporting the company's growth initiatives.
For more information on the Russell Microcap Index and the reconstitution, visit the FTSE Russell website. Additional details about NeuroOne can be found at nmtc1.com.
